Trexquant Investment LP Buys 8,553 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Trexquant Investment LP raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 127,098 shares of the biotechnology company's stock after buying an additional 8,553 shares during the period. Trexquant Investment LP owned approximately 0.20% of Blueprint Medicines worth $11,085,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in shares of Blueprint Medicines in the third quarter valued at $108,000. Captrust Financial Advisors lifted its stake in Blueprint Medicines by 3.4% in the 3rd quarter. Captrust Financial Advisors now owns 17,904 shares of the biotechnology company's stock worth $1,656,000 after acquiring an additional 582 shares in the last quarter. Verition Fund Management LLC boosted its position in Blueprint Medicines by 77.5% during the 3rd quarter. Verition Fund Management LLC now owns 9,759 shares of the biotechnology company's stock worth $903,000 after acquiring an additional 4,260 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Blueprint Medicines by 161.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company's stock valued at $45,888,000 after acquiring an additional 306,079 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new stake in shares of Blueprint Medicines during the third quarter worth approximately $5,226,000.

Analyst Upgrades and Downgrades

BPMC has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Wedbush reiterated an "outperform" rating and issued a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Guggenheim restated a "buy" rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. JPMorgan Chase & Co. increased their target price on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, StockNews.com downgraded shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $124.95.

Remove Ads

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,250 shares of the business's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $100.00, for a total transaction of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,608 shares of company stock worth $3,319,587. Insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Performance

Shares of BPMC traded down $2.53 during mid-day trading on Monday, reaching $79.15. The company's stock had a trading volume of 739,143 shares, compared to its average volume of 742,499. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The stock has a market cap of $5.06 billion, a P/E ratio of -72.83 and a beta of 0.75. Blueprint Medicines Co. has a 1-year low of $76.49 and a 1-year high of $121.90. The business has a 50-day simple moving average of $95.52 and a two-hundred day simple moving average of $94.03.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities research analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.